Ascendis Pharma A/S (ASND) NASDAQ
223.00
+2.72(+1.23%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Ascendis Pharma A/S
Sector
Healthcare
Industry
Biotechnology
Employees
1017
First IPO Date
January 28, 2015
Key Executives
| Name | Title | Pay | Year Born |
| Jan Moller Mikkelsen | President, Chief Executive Officer, Member of Executive Board & Executive Director | 0 | 1960 |
| Joseph Kelly | Head of U.S. Commercial of Endocrinology | 0 | 1969 |
| Mads Bodenhoff | Senior Vice President, Head of Finance & Principal Accounting Officer | 0 | 1970 |
| Michael Wolff Jensen | Executive Vice President, Chief Legal Officer & Member of the Executive Board | 0 | 1971 |
| Scott T. Smith | Chief Financial Officer, Executive Vice President & Member of Executive Board | 0 | 1974 |
| Pedersen Anni Lotte Kirstine Sonderbjerg | Executive Vice President, Chief Administrative Officer & Member of the Executive Board | 0 | 1961 |
| Kennett Sprogoe | Executive Vice President and Head of Research & Product Development | 0 | 1979 |
| Stina Singel | Executive Vice President & Head of Clinical Development for Oncology | 0 | 1974 |
| Chad Fugure | Vice President of Investor Relations | 0 | N/A |
| Flemming Steen Jensen | Executive Vice President of Product Supply & Quality | 0 | 1961 |
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
